Develops pharmaceutical products based on its drug delivery technologies.
DURECT Corporation, headquartered in Cupertino, California, is a dynamic biopharmaceutical company dedicated to advancing innovative medicines through its robust epigenetic regulator and pharmaceutical programs. Central to its product offerings is the ALZET product line, which includes specialized osmotic pumps and accessories utilized in research involving mice, rats, and other laboratory animals. This segment underscores DURECT's commitment to supporting scientific exploration and enhancing experimental methodologies across diverse biomedical fields.
At the forefront of its clinical development pipeline is larsucosterol (DUR-928), an orally bioavailable small molecule currently undergoing Phase IIb clinical trials. DUR-928 exhibits potential therapeutic benefits by modulating lipid metabolism, stress and inflammatory responses, and cell survival mechanisms. The molecule's investigational applications include addressing alcohol-associated hepatitis and nonalcoholic steatohepatitis, highlighting DURECT's focus on tackling complex liver diseases with unmet medical needs. Additionally, the company markets POSIMIR, an innovative post-surgical pain management product designed to deliver extended-release bupivacaine for several days in adults, alongside Methydur for the treatment of attention deficit hyperactivity disorder.
Founded in 1998, DURECT Corporation has established strategic collaborations with prominent entities such as Virginia Commonwealth University Intellectual Property Foundation, Indivior UK Ltd., and Santen Pharmaceutical Co., Ltd. These partnerships bolster the company's research and commercialization efforts, reinforcing its position as a leader in pharmaceutical innovation. With a dedicated sales force in the United States and a global network of distributors spanning Japan, Europe, and beyond, DURECT continues to expand its footprint in the healthcare industry while pursuing advancements that improve patient outcomes worldwide.